None listed
Conditions
Interventions
Intervention1: PRO1: PRO1 30c pills Dose: 4 pills daily for 4 weeks.
Control Intervention1: Placebo: Placebo pills Dose: 4 pills daily for 4 weeks.
Sponsors
Life Force Foundation Trust
Eligibility
Inclusion criteria
Inclusion criteria: 1.Healthy individuals with no apparent disease and normal routine laboratory parameters during screening 2.Intelligent enough to record carefully the facts, subjective and objective symptoms generated by the drug during proving. 3.Able to be informed of the nature of the study and willing to give written informed consent
Exclusion criteria
Exclusion criteria: 1.Any disease or condition which might compromise the hematopoietic, renal, endocrine, pulmonary, central nervous system, cardiovascular, immunological, dermatological, gastro-intestinal or any other body system 2.Persons with colour blindness. 3.Persons who have undergone surgery in last two months. 4.Planned medical / dental treatment during the proving period including herbal or dietary supplements, procedures, or medications that are likely to interfere with, or substantially alter, responsiveness to the proving substance. 5.Volunteers on regular medication (allopathic, ayurvedic, homoeopathic, naturopathic, unani, etc.) for any acute or chronic disease. 6.Participant must not be on any homoeopathic remedy in the preceding one month and have had no significant change in health status in last one month. 7.Emotionally disturbed, hysterical or anxious persons. 8.Persons having known history of allergies, food hypersensitivity, etc. 9.Women during pregnancy, puerperium and while breast-feeding. 10.Smokers who smoke more than 10 cigarettes per day 11.Recent history of alcoholism / drug addictions or unlikely to refrain from excessive alcohol consumption / drug intake during the study period 12.Participation in another clinical or proving trial during the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms experienced by provers will be recorded. Timepoint: Symptoms experienced by provers will be recorded daily and will be analyzed at the end of trial (9 week) period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety parameters - including blood investigations ECG and X ray.Timepoint: Pre( screening) and post (after completion of 4 doses of proving substance) | — |
Countries
India
Contacts
Public ContactRajesh Shah
Life Force Foundation trust
Outcome results
None listed